Host immunity to Cryptococcus neoformans

Future Microbiology

Volumn 10, Issue 4, 2015, Pages 565-581

  Rohatgi, Soma ^a   Pirofski, Liise Anne ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

acquired immunity; antibodies; B cells; cryptococcosis; Cryptococcus neoformans; Fc receptors; host response; innate immunity; macrophages; polymorphism; T cells

Indexed keywords

COMPLEMENT; FC RECEPTOR; IMMUNOGLOBULIN M;

ADAPTIVE IMMUNITY; AFRICA SOUTH OF THE SAHARA; ANTIBODY RESPONSE; B LYMPHOCYTE; BACTERIAL VIRULENCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DENDRITIC CELL; ECOLOGY; GENETIC SUSCEPTIBILITY; GRAFT RECIPIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INCIDENCE; INNATE IMMUNITY; MACROPHAGE; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PHAGOCYTOSIS; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; REVIEW; T LYMPHOCYTE; COMPLICATION; HEALTH; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY;

FILOBASIDIELLA NEOFORMANS;

ADAPTIVE IMMUNITY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; GLOBAL HEALTH; HUMANS; IMMUNITY, INNATE; IMMUNOCOMPROMISED HOST; IMMUNOLOGIC DEFICIENCY SYNDROMES; TRANSPLANT RECIPIENTS;

EID: 84927725574     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.14.132     Document Type: Review

References (186)

1. Kwon-Chung KJ, Fraser JA, Doering TL et al. Cryptococcus neoformans and Cryptococcus gattii, the etiologic agents of Cryptococcosis. Cold Spring Harb. Perspect. Med. 4(7), 1-27 (2014).
2. Andama AO, Den Boon S, Meya D et al. Prevalence and outcomes of cryptococcal antigenemia in HIV-seropositive patients hospitalized for suspected tuberculosis in Uganda. J. Acquir. Immune Defic. Syndr. 63(2), 189-194 (2013).
3. Jarvis JN, Harrison TS, Govender N et al. Routine cryptococcal antigen screening for HIV-infected patients with low CD4+ T-lymphocyte counts-time to implement in South Africa S. Afr. Med. J. 101(4), 232-234 (2011).
4. Sorrell TC. Cryptococcus neoformans variety gattii. Med. Mycol. 39(2), 155-168 (2001).
5. Lin X, Heitman J. The biology of the Cryptococcus neoformans species complex. Annu. Rev. Microbiol. 60, 69-105 (2006).
6. Litvintseva AP, Thakur R, Reller LB, Mitchell TG. Prevalence of clinical isolates of Cryptococcus gattii serotype C among patients with AIDS in sub-Saharan Africa. J. Infect. Dis. 192(5), 888-892 (2005).
7. Byrnes EJ 3rd, Li W, Lewit Y et al. Emergence and pathogenicity of highly virulent Cryptococcus gattii genotypes in the northwest United States. PLoS Pathog. 6(4), e1000850 (2010).
8. Steenbergen JN, Shuman HA, Casadevall A. Cryptococcus neoformans interactions with amoebae suggest an explanation for its virulence and intracellular pathogenic strategy in macrophages. Proc. Natl Acad. Sci. USA 98(26), 15245-15250 (2001).
9. Wang Y, Casadevall A. Decreased susceptibility of melanized Cryptococcus neoformans to UV light. Appl. Environ. Microbiol. 60(10), 3864-3866 (1994).
10. Rosas AL, Casadevall A. Melanization affects susceptibility of Cryptococcus neoformans to heat and cold. FEMS Microbiol. Lett. 153(2), 265-272 (1997).
11. Casadevall A, Pirofski LA. Accidental virulence, cryptic pathogenesis, martians, lost hosts, and the pathogenicity of environmental microbes. Eukaryot. Cell 6(12), 2169-2174 (2007).
12. Hajjeh RA, Brandt ME, Pinner RW. Emergence of cryptococcal disease: epidemiologic perspectives 100 years after its discovery. Epidemiol. Rev. 17(2), 303-320 (1995).
13. Bicanic T, Harrison TS. Cryptococcal meningitis. Br. Med. Bull. 72, 99-118 (2004).
14. Aberg JA, Price RW, Heeren DM, Bredt B. A pilot study of the discontinuation of antifungal therapy for disseminated cryptococcal disease in patients with acquired immunodeficiency syndrome, following immunologic response to antiretroviral therapy. J. Infect. Dis. 185(8), 1179-1182 (2002).
15. Jackson A, Van Der Horst C. New insights in the prevention, diagnosis, and treatment of cryptococcal meningitis. Curr. HIV/AIDS Rep. 9(3), 267-277 (2012).
16. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23(4), 525-530 (2009).
17. Pyrgos V, Seitz AE, Steiner CA, Prevots DR, Williamson PR. Epidemiology of cryptococcal meningitis in the US: 1997-2009. PLoS ONE 8(2), e56269 (2013).
18. Haddow LJ, Colebunders R, Meintjes G et al. Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: literature review and proposed clinical case definitions. Lancet Infect. Dis. 10(11), 791-802 (2010).
19. Boulware DR, Meya DB, Muzoora C et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N. Engl. J. Med. 370(26), 2487-2498 (2014).
20. Singh N, Lortholary O, Alexander BD et al. An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin. Infect. Dis. 40(12), 1756-1761 (2005).
21. Casadevall A, Pirofski LA. The damageresponse framework of microbial pathogenesis. Nat. Rev. Microbiol. 1(1), 17-24 (2003).
22. Singh N, Dromer F, Perfect JR, Lortholary O. Cryptococcosis in solid organ transplant recipients: current state of the science. Clin. Infect. Dis. 47(10), 1321-1327 (2008).
23. Singh N, Forrest G. Cryptococcosis in solid organ transplant recipients. Am. J. Transplant. 9(Suppl. 4), S192-S198 (2009).
24. Horcajada JP, Pena JL, Martinez-Taboada VM et al. Invasive Cryptococcosis and adalimumab treatment. Emerg. Infect. Dis. 13(6), 953-955 (2007).
25. Ely EW, Peacock JE Jr., Haponik EF, Washburn RG. Cryptococcal pneumonia complicating pregnancy. Medicine (Baltimore) 77(3), 153-167 (1998).
26. Winkelstein JA, Marino MC, Ochs H et al. The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients. Medicine (Baltimore) 82(6), 373-384 (2003).
27. Singh N, Husain S, De Vera M, Gayowski T, Cacciarelli TV. Cryptococcus neoformans infection in patients with cirrhosis, including liver transplant candidates. Medicine (Baltimore) 83(3), 188-192 (2004).
28. Netea MG, Brouwer AE, Hoogendoorn EH et al. Two patients with cryptococcal meningitis and idiopathic CD4 lymphopenia: defective cytokine production and reversal by recombinant interferon-gamma therapy. Clin. Infect. Dis. 39(9), e83-e87 (2004).
29. Mitchell DH, Sorrell TC, Allworth AM et al. Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome. Clin. Infect. Dis. 20(3), 611-616 (1995).
30. Lui G, Lee N, Ip M et al. Cryptococcosis in apparently immunocompetent patients. QJM 99(3), 143-151 (2006).
31. Rosen LB, Freeman AF, Yang LM et al. Anti-GM-CSF autoantibodies in patients with cryptococcal meningitis. J. Immunol. 190(8), 3959-3966 (2013).
32. Goldman DL, Khine H, Abadi J et al. Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics 107(5), E66 (2001).
33. Goldman DL, Li X, Tsirilakis K, Andrade C, Casadevall A, Vicencio AG. Increased chitinase expression and fungal-specific antibodies in the bronchoalveolar lavage fluid of asthmatic children. Clin. Exp. Allergy 42(4), 523-530 (2012).
34. Deshaw M, Pirofski LA. Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV+ and HIV-individuals. Clin. Exp. Immunol. 99(3), 425-432 (1995).
35. Abadi J, Pirofski L. Antibodies reactive with the cryptococcal capsular polysaccharide glucuronoxylomannan are present in sera from children with and without human immunodeficiency virus infection. J. Infect. Dis. 180(3), 915-919 (1999).
36. Garcia-Hermoso D, Janbon G, Dromer F. Epidemiological evidence for dormant Cryptococcus neoformans infection. J. Clin. Microbiol. 37(10), 3204-3209 (1999).
37. Jarvis JN, Lawn SD, Vogt M, Bangani N, Wood R, Harrison TS. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin. Infect. Dis. 48(7), 856-862 (2009).
38. Meya DB, Manabe YC, Castelnuovo B et al. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell countor = 100 cells/microL who start HIV therapy in resource-limited settings Clin. Infect. Dis. 51 4 448-455 2010
39. Patel S, Shin GY, Wijewardana I et al. The prevalence of cryptococcal antigenemia in newly diagnosed HIV patients in a Southwest London cohort. J. Infect. 66(1), 75-79 (2013).
40. Rajasingham R, Rolfes MA, Birkenkamp KE, Meya DB, Boulware DR. Cryptococcal meningitis treatment strategies in resourcelimited settings: a cost-effectiveness analysis. PLoS Med. 9(9), e1001316 (2012).
41. Jarvis JN, Percival A, Bauman S et al. Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-Associated cryptococcal meningitis. Clin. Infect. Dis. 53(10), 1019-1023 (2011).
42. Global Action Fund for Fungal Infections (GAFFI). www.gaffi.org
43. Olszewski MA, Zhang Y, Huffnagle GB. Mechanisms of cryptococcal virulence and persistence. Future Microbiol. 5(8), 1269-1288 (2010).
44. Vecchiarelli A, Pericolini E, Gabrielli E et al. Elucidating the immunological function of the Cryptococcus neoformans capsule. Future Microbiol. 8(9), 1107-1116 (2013).
45. Zaragoza O, Rodrigues ML, De Jesus M, Frases S, Dadachova E, Casadevall A. The capsule of the fungal pathogen Cryptococcus neoformans. Adv. Appl. Microbiol. 68, 133-216 (2009).
46. Del Poeta M. Role of phagocytosis in the virulence of Cryptococcus neoformans. Eukaryot. Cell 3(5), 1067-1075 (2004).
47. Feldmesser M, Tucker S, Casadevall A. Intracellular parasitism of macrophages by Cryptococcus neoformans. Trends Microbiol. 9(6), 273-278 (2001).
48. Alvarez M, Casadevall A. Phagosome extrusion and host-cell survival after Cryptococcus neoformans phagocytosis by macrophages. Curr. Biol. 16(21), 2161-2165 (2006).
49. Ma H, May RC. Virulence in Cryptococcus species. Adv. Appl. Microbiol. 67, 131-190 (2009).
50. Garcia-Solache MA, Casadevall A. Global warming will bring new fungal diseases for mammals. mBio 1(1), e00061-10 (2010).
51. Casadevall A. Fungi and the rise of mammals. PLoS Pathog. 8(8), e1002808 (2012).
52. Molez JF. The historical question of acquired immunodeficiency syndrome in the 1960s in the Congo River basin area in relation to cryptococcal meningitis. Am. J. Trop. Med. Hyg. 58(3), 273-276 (1998).
53. Baum GL, Artis D. Growth inhibition of Cryptococcus neoformans by cell free human serum. Am. J. Med. Sci. 241, 613-616 (1961).
54. Igel HJ, Bolande RP. Humoral defense mechanisms in cryptococcosis: substances in normal human serum, saliva, and cerebrospinal fluid affecting the growth of Cryptococcus neoformans. J. Infect. Dis. 116(1), 75-83 (1966).
55. Zaragoza O, Taborda CP, Casadevall A. The efficacy of complement-mediated phagocytosis of Cryptococcus neoformans is dependent on the location of C3 in the polysaccharide capsule and involves both direct and indirect C3-mediated interactions. Eur. J. Immunol. 33(7), 1957-1967 (2003).
56. Diamond RD, May JE, Kane MA, Frank MM, Bennett JE. The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection. J. Immunol. 112(6), 2260-2270 (1974).
57. Rhodes JC, Wicker LS, Urba WJ. Genetic control of susceptibility to Cryptococcus neoformans in mice. Infect. Immun. 29(2), 494-499 (1980).
58. Macher AM, Bennett JE, Gadek JE, Frank MM. Complement depletion in cryptococcal sepsis. J. Immunol. 120(5), 1686-1690 (1978).
59. Gates MA, Kozel TR. Differential localization of complement component 3 within the capsular matrix of Cryptococcus neoformans. Infect. Immun. 74(6), 3096-3106 (2006).
60. Pirofski LA. Of mice and men, revisited: new insights into an ancient molecule from studies of complement activation by Cryptococcus neoformans. Infect. Immun. 74(6), 3079-3084 (2006).
61. Van Asbeck EC, Hoepelman AI, Scharringa J, Herpers BL, Verhoef J. Mannose binding lectin plays a crucial role in innate immunity against yeast by enhanced complement activation and enhanced uptake of polymorphonuclear cells. BMC Microbiol. 8, 229 (2008).
62. Mansour MK, Levitz SM. Interactions of fungi with phagocytes. Curr. Opin. Microbiol. 5(4), 359-365 (2002).
63. Shao X, Mednick A, Alvarez M, Van Rooijen N, Casadevall A, Goldman DL. An innate immune system cell is a major determinant of species-related susceptibility differences to fungal pneumonia. J. Immunol. 175(5), 3244-3251 (2005).
64. Levitz SM, Tabuni A. Binding of Cryptococcus neoformans by human cultured macrophages. Requirements for multiple complement receptors and actin. J. Clin. Invest. 87(2), 528-535 (1991).
65. Griffin FM Jr. Roles of macrophage Fc and C3b receptors in phagocytosis of immunologically coated Cryptococcus neoformans. Proc. Natl Acad. Sci. USA 78(6), 3853-3857 (1981).
66. Guerra CR, Seabra SH, De Souza W, Rozental S. Cryptococcus neoformans is internalized by receptor-mediated or 'triggered' phagocytosis, dependent on actin recruitment. PLoS ONE 9(2), e89250 (2014).
67. Dan JM, Kelly RM, Lee CK, Levitz SM. Role of the mannose receptor in a murine model of Cryptococcus neoformans infection. Infect. Immun. 76(6), 2362-2367 (2008).
68. Syme RM, Spurrell JC, Amankwah EK, Green FH, Mody CH. Primary dendritic cells phagocytose Cryptococcus neoformans via mannose receptors and Fcgamma receptor II for presentation to T lymphocytes. Infect. Immun. 70(11), 5972-5981 (2002).
69. Ozinsky A, Underhill DM, Fontenot JD et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc. Natl Acad. Sci. USA 97(25), 13766-13771 (2000).
70. Shoham S, Huang C, Chen JM, Golenbock DT, Levitz SM. Toll-like receptor 4 mediates intracellular signaling without TNF-Alpha release in response to Cryptococcus neoformans polysaccharide capsule. J. Immunol. 166(7), 4620-4626 (2001).
71. Nakamura K, Miyazato A, Xiao G et al. Deoxynucleic acids from Cryptococcus neoformans activate myeloid dendritic cells via a TLR9-dependent pathway. J. Immunol. 180(6), 4067-4074 (2008).
72. Redlich S, Ribes S, Schutze S, Eiffert H, Nau R. Toll-like receptor stimulation increases phagocytosis of Cryptococcus neoformans by microglial cells. J. Neuroinflammation 10, 71 (2013).
73. Tucker SC, Casadevall A. Replication of Cryptococcus neoformans in macrophages is accompanied by phagosomal permeabilization and accumulation of vesicles containing polysaccharide in the cytoplasm. Proc. Natl Acad. Sci. USA 99(5), 3165-3170 (2002).
74. Kechichian TB, Shea J, Del Poeta M. Depletion of alveolar macrophages decreases the dissemination of a glucosylceramidedeficient mutant of Cryptococcus neoformans in immunodeficient mice. Infect. Immun. 75(10), 4792-4798 (2007).
75. Nicola AM, Robertson EJ, Albuquerque P, Derengowski Lda S, Casadevall A. Nonlytic exocytosis of Cryptococcus neoformans from macrophages occurs in vivo and is influenced by phagosomal pH. mBio 2(4), e00167-11 (2011).
76. Charlier C, Nielsen K, Daou S, Brigitte M, Chretien F, Dromer F. Evidence of a role for monocytes in dissemination and brain invasion by Cryptococcus neoformans. Infect. Immun. 77(1), 120-127 (2009).
77. Baba T. Electron microscopic cytochemical analysis of hepatic granuloma induced by Cryptococcus neoformans. Mycopathologia 104(1), 37-46 (1988).
78. Vecchiarelli A, Dottorini M, Pietrella D et al. Role of human alveolar macrophages as antigen-presenting cells in Cryptococcus neoformans infection. Am. J. Respir. Cell Mol. Biol. 11(2), 130-137 (1994).
79. Voelz K, Lammas DA, May RC. Cytokine signaling regulates the outcome of intracellular macrophage parasitism by Cryptococcus neoformans. Infect. Immun. 77(8), 3450-3457 (2009).
80. Mcquiston TJ, Williamson PR. Paradoxical roles of alveolar macrophages in the host response to Cryptococcus neoformans. J. Infect. Chemother 18(1), 1-9 (2012).
81. Davis MJ, Tsang TM, Qiu Y et al. Macrophage M1/M2 polarization dynamically adapts to changes in cytokine microenvironments in Cryptococcus neoformans infection. mBio 4(3), e00264-13 (2013).
82. Kelly RM, Chen J, Yauch LE, Levitz SM. Opsonic requirements for dendritic cell-mediated responses to Cryptococcus neoformans. Infect. Immun. 73(1), 592-598 (2005).
83. Siegemund S, Alber G. Cryptococcus neoformans activates bone marrow-derived conventional dendritic cells rather than plasmacytoid dendritic cells and downregulates macrophages. FEMS Immunol. Med. Microbiol. 52(3), 417-427 (2008).
84. Wozniak KL, Vyas JM, Levitz SM. In vivo role of dendritic cells in a murine model of pulmonary cryptococcosis. Infect. Immun. 74(7), 3817-3824 (2006).
85. Wozniak KL, Levitz SM. Cryptococcus neoformans enters the endolysosomal pathway of dendritic cells and is killed by lysosomal components. Infect. Immun. 76(10), 4764-4771 (2008).
86. Mambula SS, Simons ER, Hastey R, Selsted ME, Levitz SM. Human neutrophil-mediated nonoxidative antifungal activity against Cryptococcus neoformans. Infect. Immun. 68(11), 6257-6264 (2000).
87. Kozel TR, Pfrommer GS, Redelman D. Activated neutrophils exhibit enhanced phagocytosis of Cryptococcus neoformans opsonized with normal human serum. Clin. Exp. Immunol. 70(1), 238-246 (1987).
88. Miller MF, Mitchell TG. Killing of Cryptococcus neoformans strains by human neutrophils and monocytes. Infect. Immun. 59(1), 24-28 (1991).
89. Alcouloumre MS, Ghannoum MA, Ibrahim AS, Selsted ME, Edwards JE Jr. Fungicidal properties of defensin NP-1 and activity against Cryptococcus neoformans in vitro. Antimicrob. Agents Chemother. 37(12), 2628-2632 (1993).
90. Mednick AJ, Feldmesser M, Rivera J, Casadevall A. Neutropenia alters lung cytokine production in mice and reduces their susceptibility to pulmonary cryptococcosis. Eur. J. Immunol. 33(6), 1744-1753 (2003).
91. Holmer SM, Evans KS, Asfaw YG et al. Impact of surfactant protein D, interleukin-5, and eosinophilia on Cryptococcosis. Infect. Immun. 82(2), 683-693 (2014).
92. Feldmesser M, Casadevall A, Kress Y, Spira G, Orlofsky A. Eosinophil-Cryptococcus neoformans interactions in vivo and in vitro. Infect. Immun. 65(5), 1899-1907 (1997).
93. Yamaguchi H, Komase Y, Ikehara M, Yamamoto T, Shinagawa T. Disseminated cryptococcal infection with eosinophilia in a healthy person. J. Infect. Chemother. 14(4), 319-324 (2008).
94. Rohatgi S, Gohil S, Kuniholm MH et al. Fc gamma receptor 3A polymorphism and risk for HIV-Associated cryptococcal disease. mBio 4(5), e00573-13 (2013).
95. Schmidt S, Zimmermann SY, Tramsen L, Koehl U, Lehrnbecher T. Natural killer cells and antifungal host response. Clin. Vaccine Immunol. 20(4), 452-458 (2013).
96. Levitz SM, Dupont MP. Phenotypic and functional characterization of human lymphocytes activated by interleukin-2 to directly inhibit growth of Cryptococcus neoformans in vitro. J. Clin. Invest. 91(4), 1490-1498 (1993).
97. Ma LL, Wang CL, Neely GG, Epelman S, Krensky AM, Mody CH. NK cells use perforin rather than granulysin for anticryptococcal activity. J. Immunol. 173(5), 3357-3365 (2004).
98. Marr KJ, Jones GJ, Zheng C et al. Cryptococcus neoformans directly stimulates perforin production and rearms NK cells for enhanced anticryptococcal microbicidal activity. Infect. Immun. 77(6), 2436-2446 (2009).
99. Li SS, Kyei SK, Timm-Mccann M et al. The NK receptor NKp30 mediates direct fungal recognition and killing and is diminished in NK cells from HIV-infected patients. Cell Host Microbe 14(4), 387-397 (2013).
100. Kawakami K, Kinjo Y, Uezu K et al. Monocyte chemoattractant protein-1-dependent increase of V alpha 14 NKT cells in lungs and their roles in Th1 response and host defense in cryptococcal infection. J. Immunol. 167(11), 6525-6532 (2001).
101. Kawakami K, Kinjo Y, Yara S et al. Activation of Valpha14(+) natural killer T cells by alpha-galactosylceramide results in development of Th1 response and local host resistance in mice infected with Cryptococcus neoformans. Infect. Immun. 69(1), 213-220 (2001).
102. Taniguchi M, Harada M, Kojo S, Nakayama T, Wakao H. The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu. Rev. Immunol. 21, 483-513 (2003).
103. Huffnagle GB, Yates JL, Lipscomb MF. T cell-mediated immunity in the lung: a Cryptococcus neoformans pulmonary infection model using SCID and athymic nude mice. Infect. Immun. 59(4), 1423-1433 (1991).
104. Mody CH, Lipscomb MF, Street NE, Toews GB. Depletion of CD4+ (L3T4+) lymphocytes in vivo impairs murine host defense to Cryptococcus neoformans. J. Immunol. 144(4), 1472-1477 (1990).
105. Hill JO, Aguirre KM. CD4+ T celldependent acquired state of immunity that protects the brain against Cryptococcus neoformans. J. Immunol. 152(5), 2344-2350 (1994).
106. Buchanan KL, Doyle HA. Requirement for CD4(+) T lymphocytes in host resistance against Cryptococcus neoformans in the central nervous system of immunized mice. Infect. Immun. 68(2), 456-462 (2000).
107. Lim TS, Murphy JW. Transfer of immunity to cryptococcosis by T-enriched splenic lymphocytes from Cryptococcus neoformanssensitized mice. Infect. Immun. 30(1), 5-11 (1980).
108. Huffnagle GB, Lipscomb MF, Lovchik JA, Hoag KA, Street NE. The role of CD4+ and CD8+ T cells in the protective inflammatory response to a pulmonary cryptococcal infection. J. Leukoc. Biol. 55(1), 35-42 (1994).
109. Specht CA, Nong S, Dan JM, Lee CK, Levitz SM. Contribution of glycosylation to T cell responses stimulated by recombinant Cryptococcus neoformans mannoprotein. J. Infect. Dis. 196(5), 796-800 (2007).
110. Crowe SM, Carlin JB, Stewart KI, Lucas CR, Hoy JF. Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. J. Acquir. Immune Defic. Syndr. 4(8), 770-776 (1991).
111. Jarvis JN, Harrison TS. HIV-Associated cryptococcal meningitis. AIDS 21(16), 2119-2129 (2007).
112. Lortholary O, Poizat G, Zeller V et al. Long-term outcome of AIDS-Associated cryptococcosis in the era of combination antiretroviral therapy. AIDS 20(17), 2183-2191 (2006).
113. Zonios DI, Falloon J, Huang CY, Chaitt D, Bennett JE. Cryptococcosis and idiopathic CD4 lymphocytopenia. Medicine (Baltimore) 86(2), 78-92 (2007).
114. Van De Veerdonk FL, Netea MG. T-cell subsets and antifungal host defenses. Curr Fungal Infect. Rep. 4(4), 238-243 (2010).
115. Ma LL, Spurrell JC, Wang JF et al. CD8 T cell-mediated killing of Cryptococcus neoformans requires granulysin and is dependent on CD4 T cells and IL-15. J. Immunol. 169(10), 5787-5795 (2002).
116. Mody CH, Chen GH, Jackson C, Curtis JL, Toews GB. In vivo depletion of murine CD8 positive T cells impairs survival during infection with a highly virulent strain of Cryptococcus neoformans. Mycopathologia 125(1), 7-17 (1994).
117. Lindell DM, Moore TA, Mcdonald RA, Toews GB, Huffnagle GB. Generation of antifungal effector CD8+ T cells in the absence of CD4+ T cells during Cryptococcus neoformans infection. J. Immunol. 174(12), 7920-7928 (2005).
118. Uezu K, Kawakami K, Miyagi K et al. Accumulation of gammadelta T cells in the lungs and their regulatory roles in Th1 response and host defense against pulmonary infection with Cryptococcus neoformans. J. Immunol. 172(12), 7629-7634 (2004).
119. Wozniak KL, Kolls JK, Wormley FL Jr. Depletion of neutrophils in a protective model of pulmonary cryptococcosis results in increased IL-17A production by gammadelta T cells. BMC Immunol. 13, 65 (2012).
120. Huffnagle GB, Toews GB, Burdick MD et al. Afferent phase production of TNF-Alpha is required for the development of protective T cell immunity to Cryptococcus neoformans. J. Immunol. 157(10), 4529-4536 (1996).
121. Herring AC, Lee J, McDonald RA, Toews GB, Huffnagle GB. Induction of interleukin-12 and gamma interferon requires tumor necrosis factor alpha for protective T1-cell-mediated immunity to pulmonary Cryptococcus neoformans infection. Infect. Immun. 70(6), 2959-2964 (2002).
122. Retini C, Vecchiarelli A, Monari C, Tascini C, Bistoni F, Kozel TR. Capsular polysaccharide of Cryptococcus neoformans induces proinflammatory cytokine release by human neutrophils. Infect. Immun. 64(8), 2897-2903 (1996).
123. Hole CR, Wormley FL Jr. Vaccine and immunotherapeutic approaches for the prevention of cryptococcosis: lessons learned from animal models. Front Microbiol 3, 291 (2012).
124. Szymczak WA, Sellers RS, Pirofski LA. IL-23 dampens the allergic response to Cryptococcus neoformans through IL-17-independent and-dependent mechanisms. Am. J. Pathol. 180(4), 1547-1559 (2012).
125. Wozniak KL, Hardison SE, Kolls JK, Wormley FL. Role of IL-17A on resolution of pulmonary C. neoformans infection. PLoS ONE 6(2), e17204 (2011).
126. Jarvis JN, Casazza JP, Stone HH et al. The phenotype of the Cryptococcus-specific CD4+ memory T-cell response is associated with disease severity and outcome in HIVassociated cryptococcal meningitis. J. Infect. Dis. 207(12), 1817-1828 (2013).
127. Bicanic T, Muzoora C, Brouwer AE et al. Independent association between rate of clearance of infection and clinical outcome of HIV-Associated cryptococcal meningitis. analysis of a combined cohort of 262 patients. Clin. Infect. Dis. 49(5), 702-709 (2009).
128. Siddiqui AA, Brouwer AE, Wuthiekanun V et al. IFN-gamma at the site of infection determines rate of clearance of infection in cryptococcal meningitis. J. Immunol. 174(3), 1746-1750 (2005).
129. Jarvis JN, Meintjes G, Rebe K et al. Adjunctive interferon-gamma immunotherapy for the treatment of HIV-Associated cryptococcal meningitis: a randomized controlled trial. AIDS 26(9), 1105-1113 (2012).
130. Wormley FL Jr., Perfect JR, Steele C, Cox GM. Protection against cryptococcosis by using a murine gamma interferon-producing Cryptococcus neoformans strain. Infect. Immun. 75(3), 1453-1462 (2007).
131. Subramaniam KS, Datta K, Marks MS, Pirofski LA. Improved survival of mice deficient in secretory immunoglobulin M following systemic infection with Cryptococcus neoformans. Infect. Immun. 78(1), 441-452 (2010).
132. Rohatgi S, Pirofski LA. Molecular characterization of the early B cell response to pulmonary Cryptococcus neoformans infection. J. Immunol. 189(12), 5820-5830 (2012).
133. Szymczak WA, Davis MJ, Lundy SK, Dufaud C, Olszewski M, Pirofski LA. X-linked immunodeficient mice exhibit enhanced susceptibility to Cryptococcus neoformans Infection. mBio 4(4), e00265-13 (2013).
134. Monga DP, Kumar R, Mohapatra LN, Malaviya AN. Experimental cryptococcosis in normal and B-cell-deficient mice. Infect. Immun. 26(1), 1-3 (1979).
135. Aguirre KM, Johnson LL. A role for B cells in resistance to Cryptococcus neoformans in mice. Infect. Immun. 65(2), 525-530 (1997).
136. Feldmesser M, Mednick A, Casadevall A. Antibody-mediated protection in murine Cryptococcus neoformans infection is associated with pleotrophic effects on cytokine and leukocyte responses. Infect. Immun. 70(3), 1571-1580 (2002).
137. Rivera J, Zaragoza O, Casadevall A. Antibody-mediated protection against Cryptococcus neoformans pulmonary infection is dependent on B cells. Infect. Immun. 73(2), 1141-1150 (2005).
138. Marquis G, Montplaisir S, Pelletier M, Mousseau S, Auger P. Genetic resistance to murine cryptococcosis: increased susceptibility in the CBA/N XID mutant strain of mice. Infect. Immun. 47(1), 282-287 (1985).
139. Almeida SR, Aroeira LS, Frymuller E et al. Mouse B-1 cell-derived mononuclear phagocyte, a novel cellular component of acute non-specific inflammatory exudate. Int. Immunol. 13(9), 1193-1201 (2001).
140. Ghosn EE, Russo M, Almeida SR. Nitric oxide-dependent killing of Cryptococcus neoformans by B-1-derived mononuclear phagocyte. J. Leukoc. Biol. 80(1), 36-44 (2006).
141. Gronwall C, Vas J, Silverman GJ. Protective Roles of Natural IgM Antibodies. Front. Immunol. 3, 66 (2012).
142. Subramaniam K, Metzger B, Hanau LH et al. IgM(+) memory B cell expression predicts HIV-Associated cryptococcosis status. J. Infect. Dis. 200(2), 244-251 (2009).
143. Capolunghi F, Rosado MM, Sinibaldi M, Aranburu A, Carsetti R. Why do we need IgM memory B cells Immunol. Lett. 152(2), 114-120 (2013).
144. Subramaniam KS, Datta K, Quintero E, Manix C, Marks MS, Pirofski LA. The absence of serum IgM enhances the susceptibility of mice to pulmonary challenge with Cryptococcus neoformans. J. Immunol. 184(10), 5755-5767 (2010).
145. Rachini A, Pietrella D, Lupo P et al. An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo. Infect. Immun. 75(11), 5085-5094 (2007).
146. Torosantucci A, Chiani P, Bromuro C et al. Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence. PLoS ONE 4(4), e5392 (2009).
147. Houpt DC, Pfrommer GS, Young BJ, Larson TA, Kozel TR. Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannan. Infect. Immun. 62(7), 2857-2864 (1994).
148. Keller RG, Pfrommer GS, Kozel TR. Occurrences, specificities, and functions of ubiquitous antibodies in human serum that are reactive with the Cryptococcus neoformans cell wall. Infect. Immun. 62(1), 215-220 (1994).
149. Dromer F, Aucouturier P, Clauvel JP, Saimot G, Yeni P. Cryptococcus neoformans antibody levels in patients with AIDS. Scand. J. Infect. Dis. 20(3), 283-285 (1988).
150. Fleuridor R, Lyles RH, Pirofski L. Quantitative and qualitative differences in the serum antibody profiles of human immunodeficiency virus-infected persons with and without Cryptococcus neoformans meningitis. J. Infect. Dis. 180(5), 1526-1535 (1999).
151. Subramaniam K, French N, Pirofski LA. Cryptococcus neoformans-reactive and total immunoglobulin profiles of human immunodeficiency virus-infected and uninfected Ugandans. Clin. Diagn. Lab. Immunol. 12(10), 1168-1176 (2005).
152. Jalali Z, Ng L, Singh N, Pirofski LA. Antibody response to Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan in patients after solid-organ transplantation. Clin. Vaccine Immunol. 13(7), 740-746 (2006).
153. Carsetti R, Rosado MM, Donnanno S et al. The loss of IgM memory B cells correlates with clinical disease in common variable immunodeficiency. J. Allergy Clin. Immunol. 115(2), 412-417 (2005).
154. Hart M, Steel A, Clark SA et al. Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal disease. J. Immunol. 178(12), 8212-8220 (2007).
155. Moir S, Fauci AS. B cells in HIV infection and disease. Nat. Rev. Immunol. 9(4), 235-245 (2009).
156. Salinas-Carmona MC, Perez LI, Galan K, Vazquez AV. Immunosuppressive drugs have different effect on B lymphocyte subsets and IgM antibody production in immunized BALB/c mice. Autoimmunity 42(6), 537-544 (2009).
157. Devi SJ, Schneerson R, Egan W et al. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity. Infect. Immun. 59(10), 3700-3707 (1991).
158. Devi SJ. Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model. Vaccine 14(9), 841-844 (1996).
159. Marshall E. Dispute slows paper on "remarkable" vaccine. Science 268(5218), 1712-1715 (1995).
160. Casadevall A, Pirofski L. Insights into mechanisms of antibody-mediated immunity from studies with Cryptococcus neoformans. Curr. Mol. Med. 5(4), 421-433 (2005).
161. Zhong Z, Pirofski LA. Opsonization of Cryptococcus neoformans by human anticryptococcal glucuronoxylomannan antibodies. Infect. Immun. 64(9), 3446-3450 (1996).
162. Fleuridor R, Zhong Z, Pirofski L. A human IgM monoclonal antibody prolongs survival of mice with lethal cryptococcosis. J. Infect. Dis. 178(4), 1213-1216 (1998).
163. Maitta RW, Datta K, Chang Q et al. Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles. Infect. Immun. 72(8), 4810-4818 (2004).
164. Fleuridor R, Lees A, Pirofski L. A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection. J. Immunol. 166(2), 1087-1096 (2001).
165. Mukherjee J, Casadevall A, Scharff MD. Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization. J. Exp. Med. 177(4), 1105-1116 (1993).
166. Casadevall A, Deshaw M, Fan M, Dromer F, Kozel TR, Pirofski LA. Molecular and idiotypic analysis of antibodies to Cryptococcus neoformans glucuronoxylomannan. Infect. Immun. 62(9), 3864-3872 (1994).
167. Maitta RW, Datta K, Lees A, Belouski SS, Pirofski LA. Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice. Infect. Immun. 72(1), 196-208 (2004).
168. Pirofski LA. Polysaccharides, mimotopes and vaccines for fungal and encapsulated pathogens. Trends Microbiol. 9(9), 445-451 (2001).
169. Casadevall A, Cleare W, Feldmesser M et al. Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies. Antimicrob. Agents Chemother. 42(6), 1437-1446 (1998).
170. Larsen RA, Pappas PG, Perfect J et al. Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob. Agents Chemother. 49(3), 952-958 (2005).
171. Bryan RA, Jiang Z, Howell RC et al. Radioimmunotherapy is more effective than antifungal treatment in experimental cryptococcal infection. J. Infect. Dis. 202(4), 633-637 (2010).
172. Netea MG. Toward identification of the genetic risk profile for cryptococcal disease in HIV-infected patients. mBio 4(5), e00798-00713 (2013).
173. Ou XT, Wu JQ, Zhu LP et al. Genotypes coding for mannose-binding lectin deficiency correlated with cryptococcal meningitis in HIV-uninfected Chinese patients. J. Infect. Dis. 203(11), 1686-1691 (2011).
174. Van Sorge NM, Van Der Pol WL, Van De Winkel JG. FcgammaR polymorphisms: implications for function, disease susceptibility and immunotherapy. Tissue Antigens 61(3), 189-202 (2003).
175. Van Der Pol W, Van De Winkel JG. IgG receptor polymorphisms: risk factors for disease. Immunogenetics 48(3), 222-232 (1998).
176. Gillis C, Gouel-Cheron A, Jonsson F, Bruhns P. Contribution of human FcgammaRs to disease with evidence from human polymorphisms and transgenic animal studies. Front. Immunol. 5, 254 (2014).
177. Meletiadis J, Walsh TJ, Choi EH et al. Study of common functional genetic polymorphisms of FCGR2A, 3A and 3B genes and the risk for cryptococcosis in HIV-uninfected patients. Med. Mycol. 45(6), 513-518 (2007).
178. Hu XP, Wu JQ, Zhu LP et al. Association of Fcgamma receptor IIB polymorphism with cryptococcal meningitis in HIV-uninfected Chinese patients. PLoS ONE 7(8), e42439 (2012).
179. Parren PW, Warmerdam PA, Boeije LC et al. On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. J. Clin. Invest. 90(4), 1537-1546 (1992).
180. Salmon JE, Edberg JC, Brogle NL, Kimberly RP. Allelic polymorphisms of human Fc gamma receptor IIA and Fc gamma receptor IIIB. Independent mechanisms for differences in human phagocyte function. J. Clin. Invest. 89(4), 1274-1281 (1992).
181. Forthal DN, Landucci G, Bream J, Jacobson LP, Phan TB, Montoya B. FcgammaRIIa genotype predicts progression of HIV infection. J. Immunol. 179(11), 7916-7923 (2007).
182. Yuan R, Clynes R, Oh J, Ravetch JV, Scharff MD. Antibody-mediated modulation of Cryptococcus neoformans infection is dependent on distinct Fc receptor functions and IgG subclasses. J. Exp. Med. 187(4), 641-648 (1998).
183. Wu J, Edberg JC, Redecha PB et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J. Clin. Invest. 100(5), 1059-1070 (1997).
184. Smith KG, Clatworthy MR. FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat. Rev. Immunol. 10(5), 328-343 (2010).
185. Datta K, Pirofski LA. Towards a vaccine for Cryptococcus neoformans: principles and caveats. FEMS Yeast Res. 6(4), 525-536 (2006).
186. Huang H, Ostroff GR, Lee CK, Specht CA, Levitz SM. Characterization and optimization of the glucan particle-based vaccine platform. Clin. Vaccine Immunol. 20(10), 1585-1591 (2013).